Morgan Stanley raises its rating on Vertex Pharmaceuticals VRTX from Underweight to Equal-weight and raises its price target from $28 to 51.
Morgan Stanley says, "We upgrade VRTX to EW. CF data were better than anticipated, but key data unknowns still exist. We add VX-809 sales to our base case model."
VRTX closed at $58.12 on Monday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in